Arginine vasopressin reduces need for blood transfusion in trauma patients
Administering low dose hormone arginine vasopressin (AVP) in trauma with severe blood loss may reduce the blood products required to stabilise them by half, according to a study. This is particularly significant for patients with gun-related injuries, Each year, there are over 100,000 forearm-related injuries with over 36,000 deaths.
Arginine vasopressin is a small protein produced in the hypothalamus and stored in the pituitary gland. Arginine vasopressin is secreted into the bloodstream when blood pressure is too low and has the effect of constricting some blood vessels to bring blood pressure back up to the normal range.
The study suggests that giving AVP to trauma patients with severe blood loss could become standard practice in trauma care. This would reduce the use of blood products and their adverse side-effects during resuscitation.
Prior studies have shown that patients with severe blood loss-a condition called hemorrhagic shock= may have lost most of their stories of AVP and or their ability to secrete it into the circulation. For that reason, restoring an adequate BP in these patients often requires the infusion of more blood products, involving more potential complications, than would otherwise be needed if AVP were present. Replacing AVP artificially in hemorrhagic shock patients may be a good way to reduce unnecessary blood product-use and improve patient outcomes. This is the 1st half trial to test the idea with rigorous clinical trial design.
Current therapies for traumatic blood loss focus on haemorrhage control and blood volume replacement. Researchers conducted the study to determine whether low-dose supplementation of AVP in trauma patients and with hemorrhagic shock decreases their need for transfused blood products during resuscitation.
The randomised, double-blind placebo-controlled clinical trial enrolled 100 trauma patients from May 2013- 2017 May, who had been brought in with hemorrhagic shock and otherwise met the study criteria. All but 7 were male victims of gunshot or knife wounds.
The researchers randomised 49 of the patients to receive AVP in an initial moderate dose plus a slow infusion-during the 1st 48 hours of care- and the other 51 to receive the placebo equivalent.
Key findings include-
Patients treated with AVP for 48 hours ended up receiving an average of 1.4 litres of blood products-less than 1/2 the average amount given to those treated with placebo-2.9 litres.
The AVP group also had a markedly lower rate ( 11% vs 34%) of deep-vein-thrombosis- a blood clot in a leg vein- which is common complication in trauma patients.
Rates of complications within 30 days for the AVP and placebo groups were otherwise similar ( 55% vs 64%) and the numbers of deaths in that period were the same ( 6 in each group).
Other findings showed that although the AVP group had shorter average stays in the hospital compared to the placebo group, the relatively small number of patients in the study meant that these length-of-stay differences were not statistically significant.
Unintentional traumatic injuries are the leading cause of death in the US for people younger than 45, and the injuries often involve severe blood loss. We can replace a patient's lost blood with blood products such as packed red blood cells, fresh frozen plasma, and platelets, but use of these options can lead to serious complications and they may not fully replace key molecules in blood that are needed to support BP and the normal function of vital organs, said a researcher. The results of this trial suggest a promising way to reduce the blood needed to save the lives of patients with life-threatening with life-threatening injuries.
Additional research is necessary to determine whether including AVP improves morbidity or mortality, concluded the authors.
Arginine vasopressin is a small protein produced in the hypothalamus and stored in the pituitary gland. Arginine vasopressin is secreted into the bloodstream when blood pressure is too low and has the effect of constricting some blood vessels to bring blood pressure back up to the normal range.
The study suggests that giving AVP to trauma patients with severe blood loss could become standard practice in trauma care. This would reduce the use of blood products and their adverse side-effects during resuscitation.
Prior studies have shown that patients with severe blood loss-a condition called hemorrhagic shock= may have lost most of their stories of AVP and or their ability to secrete it into the circulation. For that reason, restoring an adequate BP in these patients often requires the infusion of more blood products, involving more potential complications, than would otherwise be needed if AVP were present. Replacing AVP artificially in hemorrhagic shock patients may be a good way to reduce unnecessary blood product-use and improve patient outcomes. This is the 1st half trial to test the idea with rigorous clinical trial design.
Current therapies for traumatic blood loss focus on haemorrhage control and blood volume replacement. Researchers conducted the study to determine whether low-dose supplementation of AVP in trauma patients and with hemorrhagic shock decreases their need for transfused blood products during resuscitation.
The randomised, double-blind placebo-controlled clinical trial enrolled 100 trauma patients from May 2013- 2017 May, who had been brought in with hemorrhagic shock and otherwise met the study criteria. All but 7 were male victims of gunshot or knife wounds.
The researchers randomised 49 of the patients to receive AVP in an initial moderate dose plus a slow infusion-during the 1st 48 hours of care- and the other 51 to receive the placebo equivalent.
Key findings include-
Patients treated with AVP for 48 hours ended up receiving an average of 1.4 litres of blood products-less than 1/2 the average amount given to those treated with placebo-2.9 litres.
The AVP group also had a markedly lower rate ( 11% vs 34%) of deep-vein-thrombosis- a blood clot in a leg vein- which is common complication in trauma patients.
Rates of complications within 30 days for the AVP and placebo groups were otherwise similar ( 55% vs 64%) and the numbers of deaths in that period were the same ( 6 in each group).
Other findings showed that although the AVP group had shorter average stays in the hospital compared to the placebo group, the relatively small number of patients in the study meant that these length-of-stay differences were not statistically significant.
Unintentional traumatic injuries are the leading cause of death in the US for people younger than 45, and the injuries often involve severe blood loss. We can replace a patient's lost blood with blood products such as packed red blood cells, fresh frozen plasma, and platelets, but use of these options can lead to serious complications and they may not fully replace key molecules in blood that are needed to support BP and the normal function of vital organs, said a researcher. The results of this trial suggest a promising way to reduce the blood needed to save the lives of patients with life-threatening with life-threatening injuries.
Additional research is necessary to determine whether including AVP improves morbidity or mortality, concluded the authors.